X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will advance phase 1/2a clinical study of AXT107 (gersizangitide), which inhibits pro-angiogenic VEGFR2 and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 26, 2023
Details:
AXT107 is an investigational drug candidate that inhibits VEGF-A and VEGF-C and activates Tie2. With its novel mechanisms of action, AXT107 has the potential to be a standard of care monotherapy.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
Proceeds will be used to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund
Deal Size: Undisclosed Upfront Cash: $35.0 million
Deal Type: Series A Financing June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
